Efficacy of LCQ908 on Cardiovascular Risk

• Status: Terminated
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study designed to evaluate the potential for the pradigastat (LCQ908) to impact cardiovascular risk.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• History of coronary artery disease

• Elevated triglycerides

• On medication to help lower cholesterol

Exclusion Criteria:

• Poorly controlled diabetic patients and/or change in diabetic medication within 12 weeks of screening

• History of myocardial infarction (heart attack) within 6 months of screening

• History of a procedure to open a blocked coronary artery within 12 months of enrollment

• History of Coronary Artery Bypass Graft (CABG) surgery

• History of congestive heart failure

• History of significant heart valve disease